T
Tianshu Liu
Researcher at Fudan University
Publications - 23
Citations - 1194
Tianshu Liu is an academic researcher from Fudan University. The author has contributed to research in topics: Chemotherapy & Regimen. The author has an hindex of 11, co-authored 23 publications receiving 848 citations.
Papers
More filters
Journal ArticleDOI
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li,Shukui Qin,Rui-Hua Xu,Thomas Yau,Brigette B.Y. Ma,Hongming Pan,Jianming Xu,Yuxian Bai,Yihebali Chi,Liwei Wang,Kun-Huei Yeh,F. Bi,Ying Cheng,Anh Tuan Le,Jen Kou Lin,Tianshu Liu,Dong Ma,Christian Kappeler,Joachim Kalmus,Tae Won Kim +19 more
TL;DR: This phase 3 trial is the second to show an overall survival benefit with regorafenib compared with placebo in patients with treatment-refractory metastatic metastatic colorectal cancer, substantiating the role of regorAFenib.
Journal ArticleDOI
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zefei Jiang,Wei Li,X. C. Hu,Qingyuan Zhang,Tao Sun,Shude Cui,Shusen Wang,Quchang Ouyang,Yongmei Yin,Cuizhi Geng,Zhongsheng Tong,Ying Cheng,Yueyin Pan,Yuping Sun,Hong Wang,Tao Ouyang,Kangsheng Gu,Jifeng Feng,Xiaojia Wang,Shubin Wang,Tianshu Liu,Jinghua Gao,Massimo Cristofanilli,Zhiqiang Ning,Xianping Lu +24 more
TL;DR: Tucidinostat plus exemestane improved progression-free survival compared with placebo plus exEMestane in patients with advanced, hormone receptor-positive, HER2-negative breast cancer.
Journal ArticleDOI
Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer
Jinwan Wang,Rui-Hua Xu,Jian Li,Yuxian Bai,Tianshu Liu,Shunchang Jiao,Guanghai Dai,Jianming Xu,Yunpeng Liu,Nanfeng Fan,Yongqian Shu,Yi Ba,Dong Ma,Shukui Qin,Leizhen Zheng,Weichang Chen,Lin Shen +16 more
TL;DR: The mDCF regimen, compared with CF, significantly prolonged PFS and OS and enhanced ORR of Chinese patients with advanced gastric cancer and achieved efficacy comparable to that of DCF but with fewer toxicities, which is appropriate for the Chinese population.
Journal ArticleDOI
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Lin Shen,Jun Guo,Qingyuan Zhang,Hongming Pan,Ying Yuan,Yuxian Bai,Tianshu Liu,Qing Zhou,Jun Zhao,Yongqian Shu,Xiaoming Huang,Siyang Wang,Jie Wang,Ai-Ping Zhou,Dingwei Ye,Ting Sun,Yujuan Gao,Silu Yang,Zoubai Wang,Jian Li,Yi-Long Wu +20 more
TL;DR: Tislelizumab was generally well tolerated among Chinese patients andAntitumor activity was observed in patients with multiple solid tumors, including nasopharyngeal carcinoma cohort.
Journal ArticleDOI
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Jifang Gong,Tianshu Liu,Qingxia Fan,Li Bai,Feng Bi,Shukui Qin,Jinwan Wang,Nong Xu,Ying Cheng,Yuxian Bai,Wei Liu,Liwei Wang,Lin Shen +12 more
TL;DR: The addition of trastuzumab to oxaliplatin/capecitabine was well tolerated and the results demonstrated encouraging efficacy.